MYCN and neoplasm: Risk stratification for patients with neuroblastoma have evolved over time, and currently utilize the International Neuroblastoma Risk Group consensus criteria, which includes age at diagnosis, disease stage, tumor pathologic features, including histology and tumor cell ploidy, and tumor genetic characteristics, such as MYCN amplification and chromosomal aberrations (3–6).